Fly News Breaks for September 5, 2017
TXMD
Sep 5, 2017 | 07:39 EDT
Cantor Fitzgerald analyst William Tanner notes TherapeuticsMD will host a conference call Wednesday with an author of the National Institutes of Health paper on vaginal estrogen and safety observations from the Women's Health Initiative Observational Study. The analyst believes that while recently published in the journal Menopause, many investors may not be familiar with the findings. Results of the analysis should provide the FDA "with additional comfort" regarding low-dose estrogen safety and support approval of TX-004 without the need for 12-month safety testing beforehand, Tanner tells investors in a research note. He keeps an Overweight rating on TherapeuticsMD with a $33 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD